Dihexa for ADHD: Adult ADHD, Prefrontal Synapses & the 2026 UK Crisis

An estimated 2.7 million UK adults may currently be waiting for an ADHD assessment, with average NHS waits of more than two years and regional waits of five to seven years — a position formally acknowledged in the late-2025 Independent Review into Mental Health Conditions, ADHD and Autism. Layered on top of the diagnostic backlog is a stubborn three-year shortage of lisdexamfetamine (Elvanse / Vyvanse) and prolonged-release methylphenidate. Predictably, search interest in “peptides for ADHD” and “Dihexa for focus” has surged. This 2026 review walks honestly through the question: what does Dihexa actually do at the synapse, how does that map onto the prefrontal cortex deficits that define ADHD, where does it stop being a substitute for licensed stimulants — and what do clinicians, patients and self-experimenters need to know before going anywhere near it?

Adult ADHD in 2026: Why the UK Is Where It Is

For decades, ADHD in the UK was treated as essentially a children’s diagnosis. That position has collapsed since 2020. Adult diagnostic services have moved from a niche specialty to the largest single source of pressure on community mental health teams in many parts of England. The numbers are unprecedented and they are rising.

The House of Commons Library briefing sets out the official scale: 562,450 open referrals for a possible ADHD diagnosis in England at the end of December 2025, of which 70.6% were adults. NHS England’s broader modelling suggests that up to 2.76 million people may be waiting for some form of ADHD assessment when undiagnosed prevalence is layered on top of formal referrals. Average waits exceed two years; in parts of London, Kent and Sussex they reach five to seven years.

The October 2024 BJPsych Bulletin commentary on adult ADHD services in crisis framed the structural problem clearly. NHS funding and specialist staffing have not kept pace with referrals; some services have closed to new referrals entirely — the Leeds Adult ADHD Service from October 2024; and spending in some integrated care boards has more than tripled in two years (£11m to £38m in Cheshire and Merseyside between 2023/24 and 2025/26 with projections of c.£51m for 2026/27), squeezing other mental health budgets.

The Independent Review into Mental Health Conditions, ADHD and Autism — chaired by Professor Peter Fonagy and triggered by the Lord Darzi investigation into the NHS — published its interim report in late 2025. Its central conclusion is important and often misreported: underlying epidemiological estimates of ADHD prevalence appear broadly stable; what has changed is the proportion of people whose ADHD is now being recognised. The implication is that the system has been chronically under-providing for a stable underlying population for thirty years and is now being asked to catch up in a decade. The Review’s full report is due in summer 2026 and will inform the Government’s 10 Year Health Plan.

Against that background, the medication supply has also been unstable. The 2023-2024 shortage of lisdexamfetamine (Elvanse / Vyvanse) and several methylphenidate prolonged-release products has eased but not resolved; the Mediwatch UK ADHD medication shortage tracker still flags intermittent regional supply problems in 2026. NHS Right to Choose has expanded access in some areas but at least nine integrated care boards have paused new Right to Choose referrals while activity plans are renegotiated, creating exactly the postcode lottery the policy was supposed to eliminate.

It is in this context — long waits, supply fragility, growing public awareness, and a generation of newly identified adults with ADHD — that interest in nootropic peptides has accelerated. The honest question is whether the science supports any of that interest, or whether it is mostly people understandably trying to do something while the system gets its act together.

The 2026 Neurobiology of ADHD: Where the Deficit Actually Lives

To assess whether Dihexa could plausibly help, we need to be precise about what ADHD is at the level of neurons. The dominant model, developed across the last twenty years and still essentially intact in 2026, places ADHD in the prefrontal cortex (PFC) and its catecholamine inputs. The seminal review work by Amy Arnsten and colleagues at Yale — The Emerging Neurobiology of ADHD: The Key Role of the Prefrontal Association Cortex and Catecholamine Influences on Prefrontal Cortical Function — remains the foundational synthesis.

Weaker Prefrontal Cortex Networks

Imaging across thousands of children and adults consistently shows that ADHD is associated with weaker structure and function of prefrontal cortex circuits, especially in the right hemisphere. Cortical thickness maturation is delayed by two to three years on average. Functional connectivity between dorsolateral PFC, dorsal anterior cingulate and parietal attention networks is reduced relative to neurotypical peers. These differences explain the canonical ADHD phenotype: difficulty sustaining attention to non-novel tasks, vulnerability to distraction, weak inhibitory control, and reduced working-memory capacity.

The Catecholamine Story: Noradrenaline and Dopamine

The PFC is uniquely sensitive to noradrenaline and dopamine. Optimal levels of both, acting at postsynaptic α2A receptors and D1 receptors on dendritic spines of PFC pyramidal cells, configure cortical microcircuits for sustained attention and working memory. Too little catecholamine input — the picture in untreated ADHD — weakens relevant network connections and reduces signal-to-noise ratio. Too much — the picture in stress, in panic and in supratherapeutic stimulant dosing — closes irrelevant ion channels too aggressively and rigidifies cognition. ADHD pharmacology lives in the narrow optimum between these two extremes.

This dose-response relationship is why stimulants work and why they have to be carefully titrated. Lisdexamfetamine, methylphenidate, dexamphetamine and (less directly) atomoxetine and guanfacine all operate on this catecholamine axis. They do not build new spines; they make better use of the spines that are there.

Dendritic Spines and Synaptic Architecture

Spines are the small membrane protrusions on dendrites where most excitatory synapses sit. The PFC has a particularly complex spine architecture, and the receptors that catecholamines act on are concentrated on these spines. In ADHD, structural studies show reduced dendritic spine maturation in PFC layer III pyramidal neurons during adolescence, with normalisation in many but not all individuals into adulthood. The structural deficit is real but partial, and it is downstream of the catecholamine signalling deficit rather than primary.

BDNF, Neuroplasticity and Stimulant Effects

Brain-derived neurotrophic factor (BDNF) is the dominant pro-synaptic, pro-plasticity growth factor in the cortex. It supports the maturation, density and function of dendritic spines through TrkB-AKT signalling. Animal studies show that methylphenidate exposure modulates BDNF expression in the prefrontal cortex, with effects that depend critically on age, dose, and duration of exposure. Atomoxetine has been reported to upregulate BDNF and TrkB signalling in the brains of adolescent spontaneously hypertensive rats — a standard ADHD model. So even the licensed pharmacology of ADHD touches BDNF and synaptic plasticity, just not as its primary mechanism.

Sleep, Iron, Sleep Apnoea, Anxiety and the Imitators

The ADHD differential diagnosis is unforgiving. Chronic sleep deprivation, untreated obstructive sleep apnoea, generalised anxiety disorder, depression, hypothyroidism, ferritin deficiency, vitamin D deficiency and post-concussion cognitive symptoms all produce attention and executive symptoms that can masquerade as ADHD. The 2025-2026 NHS commissioning push around adult ADHD has explicitly stressed that any clinical assessment includes structured evaluation of these imitators — and any self-treatment of putative ADHD with an unlicensed peptide before that has been done is poorly judged on first principles.

The BDNF/HGF Synaptic Axis: Where Dihexa Could Theoretically Enter

For the Dihexa-specific question, the relevant molecular story is the dual synaptogenic system at the PFC dendritic spine. BDNF and HGF act through different receptors (TrkB and c-Met respectively) and converge on overlapping intracellular signalling — principally PI-3K/AKT, MAPK/ERK and Rho-family GTPase pathways — that drive spine formation, maturation and stability. Both can support synaptic strengthening during learning. Both decline in conditions where attention and working memory degrade.

The relevance to ADHD rests on three connected points:

• Spine maturation is structurally implicated in ADHD. Reduced PFC dendritic spine maturation in adolescence is a reproducible finding. A pharmacological lever that builds and stabilises spines lands, in principle, on the right cellular target.
• HGF/c-Met expression maps onto the right anatomy. c-Met receptors are expressed across cortex, with notable density in prefrontal and hippocampal regions. HGF/MET signalling drives synapse formation and is upregulated in response to synaptic injury.
• Dihexa is a documented positive modulator of HGF/c-Met. The Benoist et al. (2014) study formally demonstrated that the procognitive and synaptogenic effects of angiotensin IV-derived peptides — the chemical class that gave rise to Dihexa — depend on HGF/c-Met activation. The molecular case is rigorous as far as it goes.

This is the mechanistic case for taking Dihexa seriously as a structural-plasticity adjunct in conditions with documented spine pathology. The case is genuine. It is also limited. ADHD is not Alzheimer’s disease. It is not traumatic brain injury. It is not Long COVID brain fog or menopausal cognitive change — the indications previously covered on this site (Alzheimer’s, TBI, Long COVID, menopause). In those conditions there is overt synaptic loss for synaptogenesis to repair. In ADHD the dominant deficit is signalling, not loss.

That distinction is the whole article in one sentence: a synapse-builder is most useful where synapses are being lost. ADHD is not primarily that.

Stimulants and Approved Non-Stimulants: The Only Evidence-Based Pharmacology

Any review of pharmacological options for ADHD has to start from the licensed treatments. NICE NG87 (Attention deficit hyperactivity disorder: diagnosis and management) is unambiguous: where pharmacological treatment is appropriate for adults with diagnosed ADHD, lisdexamfetamine or methylphenidate are first-line; dexamphetamine, atomoxetine, and (in specific contexts) guanfacine are alternatives. The decision is led by a specialist with shared-care arrangements with primary care.

The clinical evidence base for these medications — particularly stimulants — is enormous, replicated across multiple large randomised controlled trials and decades of clinical practice. Effect sizes for symptom reduction in adult ADHD are among the largest in psychiatric pharmacotherapy.

• Lisdexamfetamine (Elvanse / Vyvanse). A long-acting prodrug of dexamphetamine. Smooth pharmacokinetics, lower abuse liability than immediate-release amphetamine, and the most commonly prescribed adult ADHD stimulant in UK practice in 2024-2026.
• Methylphenidate prolonged-release. Equally well-evidenced. The 2023-2025 supply problems with several methylphenidate prolonged-release products were the main practical pressure on the system.
• Atomoxetine. Selective noradrenaline reuptake inhibitor; non-controlled; useful where stimulants are unsuitable (substance-use history, certain cardiac conditions, patient preference). Effect onset is slower; magnitude is generally smaller than with stimulants.
• Guanfacine prolonged-release. α2A agonist, principally used in children but with growing UK adult use. Strengthens prefrontal network function via the same α2A spine receptor that the catecholamine model centres on.
• Dexamphetamine. Older immediate- and modified-release amphetamine formulations remain in use, particularly during shortages of lisdexamfetamine.

Beyond pharmacology, NICE explicitly recommends offering structured psychological intervention — CBT specifically adapted for adult ADHD, often combined with ADHD coaching — either alongside medication or as a first-line option where medication is not suitable or not preferred. The non-pharmacological evidence base in adult ADHD has expanded materially since 2020, including ADHD-CBT, mindfulness-based interventions for adult ADHD, and structured environmental scaffolding programmes.

For the overwhelming majority of UK adults with diagnosed ADHD, this is the right ladder: assessment first, licensed medication where suitable, structured psychological intervention, lifestyle, and environment. Dihexa is not at any rung of that ladder.

Dihexa vs Stimulants: Two Different Pharmacologies

One of the most useful single comparisons for understanding why Dihexa is not a stimulant substitute is a side-by-side of mechanism. They are not in the same biological category and do not produce the same kind of effect.

The headline reading is straightforward. Stimulants do something Dihexa cannot do (rapidly correct catecholamine signalling), and Dihexa does something stimulants do not (slowly modulate synaptic structure). The relevant target organ — the prefrontal cortex — is the same. The lever is different. In ADHD, the established lever is the right one and is well-evidenced. The novel lever is unproven and is unlikely to be a useful substitute.

The Elvanse Shortage and the Wrong Reason to Try Dihexa

The 2023-2026 UK ADHD medication shortage has been the biggest single driver of off-prescription experimentation. Many adults whose stable function depends on lisdexamfetamine or methylphenidate prolonged-release have been dropped abruptly into unmedicated weeks. Search interest in “peptide for focus”, “Dihexa for ADHD” and “Vyvanse alternative” has tracked the shortage almost perfectly.

The clinical reality is that there are licensed alternatives the system can mobilise — even if the patient experience has been chaotic. Per the most recent UK ADHD medication shortage updates and several NHS trust guidance documents, the priority order during shortages is:

• Liaise with the prescribing clinician early. Pharmacy-driven cliff-edge cessation is the worst-case path; clinician-led switching is the best.
• Switch to a closely-related licensed alternative. Generic dexamphetamine, immediate-release methylphenidate, alternative MR methylphenidate brands, or atomoxetine where stimulant-free options are appropriate.
• Dose-split or stretch where supply is partial. Done with prescriber input and an explicit plan to return to original therapy when supply restores.
• Use non-pharmacological scaffolding more aggressively. Sleep, exercise, structured time-blocking, body-doubling and ADHD coaching all have meaningful per-week effect sizes.
• Document. The Government and DHSC track patient impact through MHRA Yellow Card and patient organisations — reporting medicines shortages helps drive policy response.

What is not a clinically defensible response is substituting an unlicensed peptide for a missing licensed controlled drug. There is no cross-indication evidence base. There is no monitoring framework. There is no shared-care arrangement that will continue if a clinician learns that an unlicensed compound has been added to the picture without their knowledge. And the chemical action is so different (structural plasticity vs catecholamine signalling) that the risk-benefit calculation is not even close.

That is not the same as dismissing the experience. Adults whose work, parenting and relationships depend on stable ADHD pharmacotherapy and who have been disrupted by supply issues are entitled to look for alternatives. The honest answer is that the alternatives that work are licensed medications administered through clinical channels — not research peptides.

The Fosgonimeton Parallel: Why HGF/MET Hasn’t Yet Translated

Because no controlled human trial of Dihexa exists in any condition, the most informative clinical-stage comparator is fosgonimeton (ATH-1017): a small-molecule positive modulator of the HGF/MET system developed by Athira Pharma. Fosgonimeton is not Dihexa, but it shares the core mechanism of amplifying HGF/c-Met signalling, and unlike Dihexa it has been tested in humans — including in cognitively-impaired patient populations. The story is covered in detail on the dedicated fosgonimeton page.

The lesson for ADHD is direct. Fosgonimeton was well-tolerated in Phase 1; produced procognitive effects in animal models; and entered Phase 2/3 trials in dementia with appropriate biomarker support. The Phase 3 LIFT-AD trial in Alzheimer’s disease reported in 2024 and did not meet its primary cognitive endpoint. The programme has since been refocused.

If a chemically optimised, clinically advanced HGF/MET modulator failed to translate mechanism into a measurable cognitive endpoint in a synaptically-impaired patient population (Alzheimer’s), the prior probability that an unlicensed, less-developed HGF/MET modulator (Dihexa) will translate into a measurable behavioural endpoint in a different and primarily catecholaminergic disorder (ADHD) is low. This is not pessimism for the sake of it; it is a sober reading of how cognitive endpoints behave in clinical trials.

If Someone Were Considering It: Practical Realities

This section is descriptive rather than prescriptive. There is no validated protocol for Dihexa in ADHD because there is no trial. What follows is what self-experimenters in this space describe, framed against the editorial caveats that should temper any inference.

• No ADHD-specific dose. The dose ranges discussed in the Dihexa dosage guide were derived from cognitive-enhancement use in predominantly male, predominantly neurotypical cohorts. They are not titrated to any ADHD endpoint.
• Time-course is wrong for “a hard work day”. Stimulants act inside 60-90 minutes. Synaptic structural changes from any pro-plasticity compound build over weeks. Anyone hoping Dihexa will function as a same-day focus aid will be disappointed.
• Cycling and short trials. Short cycles with explicit on/off periods are generally preferred to continuous use. See the Dihexa Review 2026 for community-reported cycling approaches.
• Stacking is high-risk in ADHD. Adult ADHD frequently coexists with anxiety, depression, sleep disturbance and treated co-morbidities; adding an unlicensed peptide to that pharmacology is interaction-heavy. The general stacking guide argues for caution; the ADHD picture amplifies that argument.
• Track and rule out placebo. ADHD symptoms are state-sensitive. Brief structured self-ratings of focus, working memory, sleep and irritability are the minimum for any unlicensed peptide trial that aspires to draw any conclusion.
• Stop at the first adverse signal. Mood destabilisation, irritability, marked sleep disturbance, palpitations or unusual cognitive effects are reasons to stop immediately and seek clinical review — particularly if combined with licensed ADHD medication.

None of this is endorsement. The clearest practical advice for adult ADHD in 2026 is the boring one. Push for a clinical assessment via the NHS or Right to Choose pathway; once diagnosed, work with a clinician on titration; do the sleep and movement work that independently improves executive function; and use environmental scaffolding aggressively. That is the evidence-based pathway.

Specific Risks in the ADHD Context

The general Dihexa safety discussion is on the side effects and risks page. Several risks become more pointed in ADHD specifically.

High-Comorbidity Population

Adult ADHD has high rates of co-occurring anxiety, depression, sleep disturbance, substance use, autism, and bipolar spectrum conditions. Many patients are on antidepressants, sleep medication, or anxiolytics. Adding an unlicensed peptide that may modulate sleep, mood and arousal into that complex pharmacology, without prescriber oversight, is high-risk. Mood destabilisation in someone with undiagnosed bipolar spectrum disorder is the specific worst case.

Adolescents and Young Adults

The prefrontal cortex continues to mature into the mid-twenties. Dihexa is plausibly active on synapse formation in exactly that maturing region. The long-term consequences of sustained pharmacological c-Met activation on a still-maturing PFC are unknown. This is a hard contraindication category.

c-Met Activation and Cancer Risk

HGF/c-Met signalling is oncogenically relevant across multiple tumour types — breast, ovarian, lung, gastric, colorectal. Anyone with a personal or family history of these cancers, or with active cancer therapy, should not consider Dihexa. This is not a theoretical worry; it is the single most-discussed safety concern for the chemical class.

Cardiovascular Stacking with Stimulants

Stimulants raise blood pressure and heart rate. Dihexa’s cardiovascular profile in chronic use is not characterised. There is no monitoring framework that captures the combined risk. If both are present, the clinical picture is one of unknown additive cardiovascular load with no clear feedback signal.

Masking Treatable Contributors

The most consequential risk is the same as in menopause and Long COVID: a vague subjective lift from an unlicensed compound can delay clinical assessment that would otherwise pick up sleep apnoea, ferritin deficiency, depression or hypothyroidism. Treating those is cheap, safe, effective and routine. Missing them costs years.

Strong Placebo and Expectation Effects

ADHD self-rating measures are highly placebo-responsive in short-duration trials. Any uncontrolled self-trial of a peptide expected to be helpful is structurally biased towards reading expectation as effect. Without a structured baseline and at least one off-cycle period, any “it worked” report is interpretable but not evidence.

Who Should Not Consider Dihexa for ADHD

• Anyone under 25 years of age — the developing prefrontal cortex is the wrong target for an unlicensed synaptogenic compound.
• Anyone without a formal ADHD assessment — including a sufficient differential diagnosis ruling out the imitators above.
• Anyone with a personal or family history of breast, ovarian, lung, gastric, or colorectal cancer.
• Anyone currently on or recently completing cancer therapy.
• Pregnant or breastfeeding individuals, or anyone trying to conceive.
• Anyone with a diagnosed bipolar or psychotic-spectrum condition.
• Anyone with significant cardiovascular disease, untreated hypertension, or unexplained palpitations.
• Anyone on multiple licensed psychiatric or controlled-drug medications without explicit prescriber sign-off on adding an unlicensed peptide.
• Anyone with active substance-use disorder where unsupervised self-experimentation poses a recovery risk.

What the Evidence Actually Supports for Adult ADHD in 2026

For balance — and because this is where almost everyone reading this page should start — here is what the 2026 evidence base genuinely supports.

• Formal assessment. Push for an NHS or NHS Right to Choose ADHD assessment. ADHD UK’s Right to Choose explainer walks through the practical steps. Where an integrated care board has paused new RTC referrals, ask explicitly when that pause ends.
• Licensed pharmacological treatment. Stimulants (lisdexamfetamine, methylphenidate, dexamphetamine), atomoxetine, or guanfacine, titrated by a specialist with shared-care arrangements with primary care, in line with NICE NG87.
• ADHD-adapted CBT and ADHD coaching. Evidence has expanded materially since 2020. Particularly useful where medication is not preferred, not tolerated, or insufficient on its own.
• Sleep, exercise, nutrition. Aerobic exercise has independent measurable effects on adult attention and working memory; protected sleep and protein-anchored eating support PFC function. None of these replaces medication where indicated, but they raise the ceiling.
• Treat the imitators and comorbidities. Sleep apnoea, ferritin/B12 deficiency, hypothyroidism, anxiety, depression and substance use all need addressing in their own right, not buried under a peptide trial.
• Environmental scaffolding. Externalised lists, time-blocking, body-doubling, calendar-anchored work, single-tab discipline, low-stimulus environments. These are unglamorous but have the largest day-to-day effect on most adults with ADHD.
• Vetted patient-facing resources. The NHS ADHD pages, ADHD UK, and the ADHD Foundation are useful UK-specific starting points.

The Bottom Line in 2026

ADHD is a real, biological, primarily catecholaminergic disorder of prefrontal cortex network function. The UK is in a structural crisis of adult diagnosis and medication supply that the Fonagy Independent Review has formally acknowledged and that the 10 Year Health Plan is intended to address. While that catches up, demand for off-prescription “focus aids” will continue to rise — and for many adults that demand is genuinely about being able to function, not about cognitive enhancement for its own sake.

Dihexa, with its direct activation of the HGF/c-Met spine-formation pathway, has a real but narrow place in the broader cognitive-pharmacology conversation. In ADHD specifically, that place is small. The dominant deficit is signalling, not synapse loss. The clinical evidence in ADHD is zero. The closest clinical-stage relative (fosgonimeton) confirmed feasibility of HGF/MET modulation in humans but missed its Phase 3 cognitive endpoint. And the comorbidity profile of adult ADHD — high-trait anxiety, depression, sleep fragility, polypharmacy — makes adding an unlicensed compound to the picture risk-heavy and yield-light.

The honest 2026 reading is the same as for menopause and Long COVID brain fog: clinical assessment first, licensed treatment second, structured non-pharmacological work always, off-label adjuncts only with prescriber oversight, research chemicals essentially last — if at all. The right next step for most readers of this page is not a peptide vendor. It is an ADHD UK Right to Choose referral letter and a GP appointment.

Frequently Asked Questions

Related Reading on Dihexa.co.uk

• Dihexa for Anxiety & Chronic Stress (2026) — comorbid anxiety in adult ADHD is the rule, not the exception; the same prefrontal-circuit story applies.
• Dihexa for Menopause & Perimenopause Brain Fog (2026) — companion review of a closely related cognitive-symptom phenotype.
• Dihexa for Long COVID Brain Fog (2026) — another major brain-fog indication where the synaptic case is stronger than in ADHD.
• Dihexa for Depression & Mood — the synaptogenic hypothesis of depression and its overlap with adult ADHD comorbidity.
• Dihexa for TBI, Concussion & Stroke Recovery — the neurorepair indication where HGF/c-Met has the cleanest mechanistic case.
• Dihexa vs BDNF: What “10 Million Times More Potent” Actually Means — an in-depth look at the most-cited claim.
• Dihexa Review 2026 — effects timeline, oral vs sublingual, cycling protocols.
• Dihexa Stacking Guide — why stacking with licensed psychiatric pharmacology needs clinician oversight.
• Dihexa for Cognitive Enhancement — the broader healthy-adult conversation.
• Mechanism of Action — HGF/c-Met, PI-3K/AKT, dendritic spines.
• Side Effects & Risks — the general safety picture.
• UK Legal Status — where Dihexa sits in UK law and MHRA advertising rules.
• Fosgonimeton & Athira — the cautionary Phase 3 story.

External Authoritative Sources Cited

• House of Commons Library. ADHD statistics (England) FAQ.
• UK Government (2025). Independent review into mental health conditions, ADHD and autism: interim report.
• UK adult ADHD services in crisis (BJPsych Bulletin, 2024).
• NICE NG87. Attention deficit hyperactivity disorder: diagnosis and management.
• Arnsten AFT. The Emerging Neurobiology of ADHD: The Key Role of the Prefrontal Association Cortex (2009).
• Arnsten AFT. Catecholamine Influences on Prefrontal Cortical Function: Relevance to Treatment of ADHD (2011).
• Benoist CC et al. The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the HGF/c-Met System.
• Wright JW et al. AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway (2021).
• Royea J & Hamel E. Cognitive benefits of Angiotensin IV and Angiotensin-(1-7): a systematic review of experimental studies.
• Calipari ES et al. Juvenile methylphenidate reduces prefrontal cortex plasticity via D3 receptor and BDNF in adulthood (Frontiers in Synaptic Neuroscience, 2014).
• HGF and MET: From Brain Development to Neurological Disorders (Frontiers, 2021).
• Mediwatch UK ADHD medication shortage tracker (live updates).
• NELFT NHS Foundation Trust. National supply shortage of ADHD medicines.
• ADHD UK. NHS Right to Choose explainer.
• NHS ADHD information hub.